Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 4Active not recruiting 4Completed 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 27Cisplatin 17Nivolumab 14Cyclophosphamide 14Carboplatin 13Radiation 12Paclitaxel 12Doxorubicin 11Radiotherapy 10Radiotherapy, Intensity-Modulated 9Cytarabine 9Vincristine 8Magnetic Resonance Spectroscopy 8Docetaxel 8Bevacizumab 8Radiosurgery 7Leucovorin 7Fluorouracil 7Etoposide 7Specimen Handling 6Prednisone 6Pemetrexed 6Irinotecan 6Injections 6Gemcitabine 6Dexamethasone 6venetoclax 5tislelizumab 5fludarabine 5enzalutamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × trifluridine tipiracil drug combination × 30 days × Clear all
NCT05064059 2026-05-26

MK-4280A-007

Merck Sharp & Dohme LLC

Phase 3 Completed
441 enrolled 24 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT04489173 2026-05-22

TIBET

Borstkanker Onderzoek Groep

Phase 2 Completed
52 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡